Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis

被引：3
作者：
Ferenci, P. [1 ]
Dusheiko, G. [2 ]
机构：
[1] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, A-1090 Vienna, Austria
[2] UCL Inst Liver & Digest Hlth, London, England
来源：
GUT | 2014年 / 63卷 / 07期
关键词：
CHRONIC HEPATITIS-C; GENOTYPE; INFECTION; BOCEPREVIR; TELAPREVIR; COHORT;
D O I：
10.1136/gutjnl-2013-306480
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1033 / +
页数：2
相关论文
共 14 条
  • [1] Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy
    Afdhal, Nezam H.
    Dusheiko, Geoffrey M.
    Giannini, Edoardo G.
    Chen, Pei-Jer
    Han, Kwang-Hyub
    Mohsin, Aftab
    Rodriguez-Torres, Maribel
    Rugina, Sorin
    Bakulin, Igor
    Lawitz, Eric
    Shiffman, Mitchell L.
    Tayyab, Ghias-Un-Nabi
    Poordad, Fred
    Kamel, Yasser Mostafa
    Brainsky, Andres
    Geib, James
    Vasey, Sandra Y.
    Patwardhan, Rita
    Campbell, Fiona M.
    Theodore, Dickens
    [J]. GASTROENTEROLOGY, 2014, 146 (02) : 442 - +
  • [2] Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large US cohort
    Backus, L. I.
    Belperio, P. S.
    Shahoumian, T. A.
    Cheung, R.
    Mole, L. A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (01) : 93 - 103
  • [3] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
    Bacon, Bruce R.
    Gordon, Stuart C.
    Lawitz, Eric
    Marcellin, Patrick
    Vierling, John M.
    Zeuzem, Stefan
    Poordad, Fred
    Goodman, Zachary D.
    Sings, Heather L.
    Poordad, Fred
    Goodman, Zachary D.
    Sings, Heather L.
    Boparai, Navdeep
    Burroughs, Margaret
    Brass, Clifford A.
    Albrecht, Janice K.
    Esteban, Rafael
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) : 1207 - 1217
  • [4] Treatment of chronic hepatitis C genotype 1 patients at an academic center in europe involved in prospective, controlled trials: Is there a selection bias?
    Beinhardt, Sandra
    Staettermayer, Albert F.
    Rutter, Karoline
    Maresch, Judith
    Scherzer, Thomas M.
    Steindl-Munda, Petra
    Hofer, Harald
    Ferenci, Peter
    [J]. HEPATOLOGY, 2012, 55 (01) : 30 - 38
  • [5] Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
    Colombo, M.
    Fernandez, I.
    Abdurakhmanov, D.
    Ferreira, P. A.
    Strasser, S. I.
    Urbanek, P.
    Moreno, C.
    Streinu-Cercel, A.
    Verheyen, A.
    Iraqi, W.
    DeMasi, R.
    Hill, A.
    Laeuffer, J. M.
    Lonjon-Domanec, I.
    Wedemeyer, H.
    [J]. GUT, 2014, 63 (07) : 1150 - 1158
  • [6] A Prospective Study of the Rate of Progression in Compensated, Histologically Advanced Chronic Hepatitis C
    Dienstag, Jules L.
    Ghany, Marc G.
    Morgan, Timothy R.
    Di Bisceglie, Adrian M.
    Bonkovsky, Herbert L.
    Kim, Hae-Young
    Seeff, Leonard B.
    Szabo, Gyongyi
    Wright, Elizabeth C.
    Sterling, Richard K.
    Everson, Gregory T.
    Lindsay, Karen L.
    Lee, William M.
    Lok, Anna S.
    Morishima, Chihiro
    Stoddard, Anne M.
    Everhart, James E.
    [J]. HEPATOLOGY, 2011, 54 (02) : 396 - 405
  • [7] Surrogate end points in clinical trials: Are we being misled?
    Fleming, TR
    DeMets, DL
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) : 605 - 613
  • [8] Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890
    Hezode, Christophe
    Fontaine, Helene
    Dorival, Celine
    Larrey, Dominique
    Zoulim, Fabien
    Canva, Valerie
    de Ledinghen, Victor
    Poynard, Thierry
    Samuel, Didier
    Bourliere, Marc
    Zarski, Jean-Pierre
    Raabe, Jean-Jacques
    Alric, Laurent
    Marcellin, Patrick
    Riachi, Ghassan
    Bernard, Pierre-Henri
    Loustaud-Ratti, Veronique
    Metivier, Sophie
    Tran, Albert
    Serfaty, Lawrence
    Abergel, Armand
    Causse, Xavier
    Di Martino, Vincent
    Guyader, Dominique
    Lucidarme, Damien
    Grando-Lemaire, Veronique
    Hillon, Patrick
    Feray, Cyrille
    Thong Dao
    Cacoub, Patrice
    Rosa, Isabelle
    Attali, Pierre
    Petrov-Sanchez, Ventzislava
    Barthe, Yoann
    Pawlotsky, Jean-Michel
    Pol, Stanislas
    Carrat, Fabrice
    Bronowicki, Jean-Pierre
    [J]. JOURNAL OF HEPATOLOGY, 2013, 59 (03) : 434 - 441
  • [9] Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
    Jacobson, Ira M.
    McHutchison, John G.
    Dusheiko, Geoffrey
    Di Bisceglie, Adrian M.
    Reddy, K. Rajender
    Bzowej, Natalie H.
    Marcellin, Patrick
    Muir, Andrew J.
    Ferenci, Peter
    Flisiak, Robert
    George, Jacob
    Rizzetto, Mario
    Shouval, Daniel
    Sola, Ricard
    Terg, Ruben A.
    Yoshida, Eric M.
    Adda, Nathalie
    Bengtsson, Leif
    Sankoh, Abdul J.
    Kieffer, Tara L.
    George, Shelley
    Kauffman, Robert S.
    Zeuzem, Stefan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) : 2405 - 2416
  • [10] Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting
    Maasoumy, Benjamin
    Port, Kerstin
    Markova, Antoaneta Angelova
    Serrano, Beatriz Calle
    Rogalska-Taranta, Magdalena
    Sollik, Lisa
    Mix, Carola
    Kirschner, Janina
    Manns, Michael P.
    Wedemeyer, Heiner
    Cornberg, Markus
    [J]. PLOS ONE, 2013, 8 (02):
12